• US FDA grants Fast Track designation for Shire’s SHP655 pharmaceutical-technology
    March 24, 2017
    The US Food and Drug Administration (FDA) has granted Fast Track designation for Shire’s recombinant ADAMTS13 (SHP655 or previously known as BAX930) to treat acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).
PharmaSources Customer Service